Сравнение

CagriSema vs. Eloralintide

Два пептида рядом — идентичность, доказательная база, правовой статус и известные нежелательные явления.

Идентичность

Категория

Метаболизм

Номер CAS

нет данных

Молекулярная масса

нет данных

Период полувыведения

нет данных

Последовательность

нет данных

Механизм действия

CagriSema

CagriSema combines two satiety pathways in one weekly injection: the amylin analogue cagrilintide and the GLP-1 agonist semaglutide. Both suppress appetite and food intake — together more than either component alone.

Eloralintide

Eloralintide selectively activates amylin receptors (preferentially AMY1R) and promotes satiety. The approach targets weight loss via the amylin axis, complementary to or independent of GLP-1 agents.

Доказательная база

Наивысшая доказательность

РКИ на людях

Исследования

из них на людях

Зафиксированные эффекты

Открытые противоречия

Задокументированные нежелательные явления

Правовой статус

Country	CagriSema	Eloralintide
Германия	Не одобрено	Не одобрено
США	Не одобрено	Не одобрено

Полные записи

Frequently asked questions

What is the difference between CagriSema and Eloralintide?: CagriSema is classified as "Метаболизм", while Eloralintide is classified as "Метаболизм". CagriSema: CagriSema is a fixed-dose combination of the amylin analogue cagrilintide and the GLP-1 agonist semaglutide (Novo Nordisk), in late-stage development for obesity and type 2 diabetes. Eloralintide: Eloralintide is a selective, long-acting amylin receptor agonist from Eli Lilly for once-weekly subcutaneous use — under investigation for obesity, alone and combined with incretin therapy. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
Which peptide is better supported by science, CagriSema or Eloralintide?: The highest available evidence level is "РКИ на людях" for CagriSema and "РКИ на людях" for Eloralintide. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
What is the legal status of CagriSema and Eloralintide in Germany and the United States?: Германия: CagriSema — Не одобрено, Eloralintide — Не одобрено. США: CagriSema — Не одобрено, Eloralintide — Не одобрено. These are factual summaries with source and review date on the individual pages.

Country

CagriSema

Eloralintide

Германия

Не одобрено

США

Не одобрено

Frequently asked questions

What is the difference between CagriSema and Eloralintide?

CagriSema is classified as "Метаболизм", while Eloralintide is classified as "Метаболизм". CagriSema: CagriSema is a fixed-dose combination of the amylin analogue cagrilintide and the GLP-1 agonist semaglutide (Novo Nordisk), in late-stage development for obesity and type 2 diabetes. Eloralintide: Eloralintide is a selective, long-acting amylin receptor agonist from Eli Lilly for once-weekly subcutaneous use — under investigation for obesity, alone and combined with incretin therapy. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.

Which peptide is better supported by science, CagriSema or Eloralintide?

The highest available evidence level is "РКИ на людях" for CagriSema and "РКИ на людях" for Eloralintide. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.

What is the legal status of CagriSema and Eloralintide in Germany and the United States?

Германия: CagriSema — Не одобрено, Eloralintide — Не одобрено. США: CagriSema — Не одобрено, Eloralintide — Не одобрено. These are factual summaries with source and review date on the individual pages.